DiversityInc names Lilly a top company for diversity
25 April 2012 | By Eli Lilly and Company
Eli Lilly and Company has been named to the 2012 DiversityInc Top 50 Companies for Diversity list...
List view / Grid view
25 April 2012 | By Eli Lilly and Company
Eli Lilly and Company has been named to the 2012 DiversityInc Top 50 Companies for Diversity list...
25 April 2012 | By AstraZeneca
AstraZeneca and The Medicines Company announced a global collaboration...
25 April 2012 | By Novartis
Novartis announced that the European Commission has approved Signifor®...
25 April 2012 | By Amgen
Amgen and Mustafa Nevzat Pharmaceuticals have announced an agreement under which Amgen will acquire 95.6 percent of shares in MN...
24 April 2012 | By B&W Tek Inc
B&W Tek, Inc., has announced its 18th patent since the company’s establishment in 1997...
24 April 2012 | By Gerresheimer AG
Gerresheimer will be displaying its comprehensive range of tubular glass based primary packaging solutions at Interphex...
24 April 2012 | By Novo Nordisk
Novo Nordisk and the Oxford University announce a new partnership...
23 April 2012 | By AstraZeneca
Deal includes lead product lesinurad in Phase III development for gout...
23 April 2012 | By Takeda Pharmaceutical Company Limited
For the treatment of iron deficiency anaemia in adult chronic kidney disease patients...
23 April 2012 | By AstraZeneca
In combination with other glucose-lowering medicinal products including insulin...
23 April 2012 | By GlaxoSmithKline Plc
Announcement follows divestment of brands in USA, Canada & Europe...
23 April 2012 | By Novo Nordisk
Two studies show a significant reduction in the rates of nocturnal hypoglycaemia by 25%, compared to insulin glargine...
23 April 2012 | By Amgen
Amgen has announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away...
20 April 2012 | By Sanofi
Full CARE-MS II results for Alemtuzumab to be unveiled...
20 April 2012 | By Novartis
Upon approval, Jakavi(TM) (INC424, ruxolitinib) will be the first EU approved JAK inhibitor developed to treat patients with myelofibrosis, a rare blood cancer...